| P/E (FY) | 38.3 | Sales (TTM) | ₩4.16T |
| Earnings (TTM) | ₩1.03T | ROE | 5.94% |
| Net Margin | 24.74% | ROIC | 6.37% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 7.64% | Sales Growth 3Y | 22.15% |
Celltrion, Inc. is a biopharmaceutical company that develops, produces and sells medicinal products, focusing on biosimilars. Its products include Remsima, Truxima, Herzuma, Yuflyma, Vegzelma, Omlyclo, Steqeyma, Avtozma, Zymfentra and Regkirona, addressing conditions such as rheumatoid arthritis, inflammatory bowel disease, various cancers, asthma and COVID-19. The company is also developing additional biosimilars in Phase 3 trials and distributes its products in approximately 100 countries, including the United States and Europe.
| Market Cap | $26.77B | Trading Days | 3973 |
| 52W High | 239047.61 |
| 52W Low | 158500.00 |
| % Off High | −25.25% |
| YTD | 3.67% | 1Y | 5.59% |
| 3Y | 53.50% | 5Y | −10.95% |
| 10Y | 168.88% | Since incept. (ann.) | 18.62% |
| Ann. Volatility (1Y) | 42.40% | Ann. Volatility (3Y) | 39.15% |
| Sharpe (1Y) | 0.35 | Sharpe (3Y) | 0.62 |
| Max Drawdown (1Y) | −32.65% | Max Drawdown (3Y) | −32.65% |
| Beta (3Y, vs SPY) | 0.66 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| DGX | QUEST DIAGNOSTICS INC | $26.04B | 27.0 |
| INCY | INCYTE CORP | $25.96B | 20.3 |
| LH | LABCORP HOLDINGS INC. | $25.77B | 30.0 |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $28.06B | 33.0 |
| DXCM | DEXCOM INC | $28.88B | 35.8 |
| GEHC | GE HealthCare Technologies Inc. | $29.16B | 14.1 |
| ILMN | ILLUMINA, INC. | $29.20B | 35.4 |
| 4503.T | Astellas Pharma Inc. | $24.40B | 13.6 |
| ROIV | Roivant Sciences Ltd. | $24.34B | — |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.72B | 49.6 |
| RMD | RESMED INC | $30.31B | 22.0 |
| BIIB | BIOGEN INC. | $30.36B | 23.4 |
